We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmentalized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B cell depletion ameliorates the disease course and pathology.

Graphical Abstract

我们开发了一种基于纳米技术的细胞介导的药物递送系统，通过将纳米颗粒与抗 CD20 单克隆抗体结合，加载髓鞘抗原特异性 T 细胞。抗 CD20 抗体是多发性硬化症 (MS) 的当前治疗方法 (ocrelizumab)，这是一种中枢神经系统 (CNS) 的慢性炎症和自身免疫性疾病。CD20 耗竭与活动性复发性和进展性 MS 的疗效相关，但可能无法有效靶向中枢神经系统中分隔的炎症细胞。在我们的工作中，含有纳米颗粒-抗 CD20 复合物的 T 细胞在小鼠体内的静脉内转移会导致脾脏和大脑中的 B 细胞消耗，而单独注射抗 CD20 仅消耗脾脏中的 B 细胞。在实验性自身免疫性脑脊髓炎 (EAE)、MS 动物模型、

图形概要